首页>投融资
Ventus Therapeutics
捐赠/众筹/授予
Ventus Therapeutics is a biotechnology company developing novel small molecule medicines that target the innate immune system.In February 2022, the company had closed a $140 million Series C financing co-led by SoftBank Vision Fund 2, RA Capital Management, Qatar Investment Authority, Andreessen Horowitz, BVF Partners L.P., Casdin Capital, Cormorant Asset Management, Fonds de solidarité FTQ, Alexandria Venture Investments, GV (formerly Google Ventures) and Versant Ventures
基本信息
-
公司全称Ventus Therapeutics Inc
-
类型新型小分子药物开发商
-
产业领域医药研发/制造、化学&生物药
-
公司人数15~50人
-
地址7150 Frederick-Banting Saint-Laurent MONTREAL QUEBEC H4S 2A1; CA;
-
联系电话514-397-9517
-
邮箱info@ventustx.com
-
成立时间2019-01-01
投融资
-
2023-04-20捐赠/众筹/授予15万美元Michael J. Fox Foundation for Parkinson’s Research
-
2022-02-09C轮1.4亿美元GVAlexandria Venture InvestmentsCasdin CapitalRA Capital鱼鹰资管Qatar Investment Authority软银愿景基金Andreessen HorowitzFonds de Solidarite FTQVersant VenturesBVF Partners
-
2021-04-08B轮1亿美元GVAlexandria Venture InvestmentsCasdin CapitalRA Capital鱼鹰资管Fonds de Solidarite FTQVersant VenturesBVF Partners
-
2020-05-06A轮6000万美元GVVersant Ventures
- 加载更多
相关投融资企业
A轮
Ouro Medicines是一家免疫重置公司，通过结合科学专业知识、通过临床推进细胞耗竭疗法的跟踪记录以及强大的管道来正面应对慢性免疫介导的疾病。Ouro最领先的候选产品是OM336，这是一种最近从康诺亚生物获得许可的BCMA靶向的双特异性TCE。
A轮
RhyGaze开发一种新的基因疗法，旨在恢复患者的视力。该公司的治疗技术将光传感器基因专门传递给失去光敏感性的视锥细胞，并修复其检测光的能力，使医疗保健行业能够为失明患者提供视力恢复。
未公开
Thetis Pharmaceuticals LLC is a pharmaceutical company focused on the development of prescription drugs for diabetes, hypertriglyceridemia and dyslipidemia. Thetis's proprietary HEALER technology (High Efficiency Amino Lipid Enabled Release) uses transformative ionic chemistry to revitalize proven therapeutic agents and generated solid, stable APIs.In July 2021, Thetis Pharmaceuticals LLC announced the launch of a new program in cancer TP-317, which is a Resolvin E1 therapy for the treatment of solid tumour cancers published in the Journal of Experimental Medicine.In May 2013, the company raised $5.7 million through a series A financing.In September 2011, Thetis secured first round funding. At that time, the company planned to secure additional capital in the second half of 2012
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息